Executive Summary
Drug discovery is increasingly becoming a computational problem as pharmaceutical companies generate enormous amounts of biological, chemical, genomic, and clinical data.
Foundation models are emerging as an important technology within this transformation.
Unlike traditional AI models designed for a narrowly defined task, foundation models are trained on broad datasets and can be adapted to multiple applications. In life sciences, these models can work with different forms of biological and chemical information, including molecular structures, proteins, genomic sequences, scientific literature, images, and experimental data.
Their potential extends across the discovery process.
Foundation models could help researchers identify disease mechanisms, predict protein structures, design molecules, interpret biological data, and prioritize experiments.
The most significant opportunity may come from combining these models with laboratory automation and high-throughput experimentation.
This could create a continuous cycle in which models generate hypotheses, laboratories test them, and experimental results improve subsequent predictions.
The result could be a more integrated and scalable drug discovery process.
What Are Foundation Models in Drug Discovery?
Foundation models are large AI models trained on broad datasets that can support multiple downstream applications.
In drug discovery, these models can be trained or adapted to understand biological and chemical information.
Depending on their design, they may process:
- Molecular structures and chemical properties
- Protein sequences and structures
- Genomic and transcriptomic data
- Scientific publications
- Biological images
- Experimental results
Rather than building a separate model for every individual prediction, researchers can use a foundational model as a starting point and adapt it to specific scientific problems.
This can create a more flexible AI infrastructure for pharmaceutical R&D.
How Can Foundation Models Improve Target Discovery?
Identifying promising therapeutic targets is one of the earliest challenges in drug development.
Researchers need to understand disease biology, identify mechanisms that can potentially be modified, and determine whether changing a target could produce a meaningful therapeutic effect.
Foundation models can analyze relationships across large biological datasets to identify patterns that may be difficult to detect through conventional analysis.
They can integrate information from scientific literature, genomic datasets, protein information, disease associations, and other sources.
This can help researchers generate and prioritize hypotheses.
Importantly, computational predictions still require biological validation. A model can suggest a promising target, but laboratory experiments are needed to establish whether the underlying biological hypothesis is correct.
Can Foundation Models Design New Molecules?
Molecular design is one of the most visible applications of generative AI in drug discovery.
Foundation models can learn patterns in chemical structures and molecular properties and use that knowledge to generate or evaluate potential compounds.
Researchers can provide desired characteristics, such as target affinity, selectivity, solubility, or other properties, and models can help identify candidates that may satisfy multiple requirements.
This creates the possibility of moving from searching existing chemical libraries toward generating new molecular designs.
The challenge is that a computationally attractive molecule may still fail because of toxicity, pharmacokinetics, manufacturability, or other biological factors.
The value of foundation models therefore depends on their integration with experimental testing.
How Are Protein Models Changing Drug Discovery?
Proteins are central to biological function and are important targets for many medicines.
Advances in AI-based protein modeling have improved researchers’ ability to study protein structures, interactions, and functions.
Foundation models can learn patterns from large collections of protein sequences and related biological information.
These capabilities can support protein structure prediction, protein engineering, target analysis, and the design of molecules that interact with specific proteins.
As models become more capable of understanding relationships between proteins, molecules, and biological systems, they could support increasingly sophisticated forms of computational drug design.
What Role Does Multimodal AI Play?
Biology does not exist in isolated datasets.
A drug discovery question may involve molecular structure, protein behavior, genomic information, experimental results, microscopy images, and scientific literature simultaneously.
Multimodal foundation models are designed to work across different forms of information.
This creates the possibility of analyzing connections between data types rather than treating each dataset separately.
For example, a model could combine molecular information with biological measurements and experimental results to help researchers understand why a particular compound produces a specific response.
Multimodal capabilities could therefore move AI closer to the complexity of biological research itself.
How Could Foundation Models Accelerate Experimentation?
The greatest value of AI may not come from making individual predictions faster.
It may come from helping researchers decide which experiments are most valuable.
A foundation model can generate hypotheses or rank potential candidates. Laboratory automation can then test selected possibilities.
The resulting data can be incorporated into the computational system, improving future predictions.
This creates a cycle:
Model prediction → Experiment → Data → Model improvement → Next experiment
The approach can reduce unnecessary experimentation while allowing researchers to explore more possibilities within the same research timeframe.
Can Foundation Models Reduce Drug Discovery Costs?
Drug discovery involves substantial experimentation and high failure rates.
If AI can identify weak candidates earlier or prioritize more promising ones, companies may be able to allocate laboratory resources more efficiently.
Potential benefits include:
- Faster candidate prioritization
- Reduced experimental redundancy
- More efficient screening
- Earlier identification of potential liabilities
- Better use of laboratory resources
However, AI does not remove the cost of experimental validation.
The economic value depends on whether computational predictions consistently improve decisions and reduce expensive downstream failures.
What Are the Biggest Challenges?
Foundation models introduce significant technical and scientific challenges.
The quality of model outputs depends heavily on the quality and diversity of the training data.
Biological datasets can also contain biases, missing information, inconsistent measurements, and limited representation of certain diseases or populations.
Other challenges include:
- Model interpretability
- Hallucinated or biologically implausible outputs
- Data ownership and intellectual property
- Validation of predictions
- Integration with laboratory systems
- Computational costs
- Reproducibility
A model that performs well on benchmark datasets may not necessarily produce useful discoveries in a real pharmaceutical research environment.
How Should Pharma Companies Adopt Foundation Models?
Pharmaceutical companies should treat foundation models as components of a broader discovery strategy rather than standalone solutions.
Successful implementation requires high-quality scientific data, appropriate computational infrastructure, laboratory integration, and researchers who can evaluate model outputs.
Companies can begin with well-defined discovery problems where outcomes can be measured.
They should also establish clear processes for validating AI-generated hypotheses before they influence major development decisions.
The strongest architectures are likely to combine foundation models with proprietary datasets and experimental capabilities.
This can create a feedback loop that becomes increasingly valuable as more experiments generate additional data.
What Will Foundation Model-Driven Drug Discovery Look Like?
The future drug discovery environment may combine foundation models, autonomous laboratories, digital twins, high-throughput screening, and increasingly sophisticated biological datasets.
Researchers could interact with AI systems through natural language, define a scientific objective, and receive proposed targets, molecules, experiments, and supporting evidence.
Automated laboratories could then execute selected experiments and return results directly to the computational environment.
This would not eliminate scientists.
Instead, researchers could spend more time defining scientific questions, evaluating evidence, interpreting unexpected results, and deciding which research directions deserve deeper investigation.
The discovery process could become increasingly continuous rather than organized around isolated experimental cycles.
Conclusion
Foundation models are becoming an important part of the next generation of computational drug discovery.
Their ability to learn from broad biological and chemical datasets can support target discovery, molecular design, protein modeling, multimodal analysis, and experimental prioritization.
Their greatest potential may emerge when they are connected to physical experimentation.
AI can propose what to investigate, automated laboratories can test those hypotheses, and experimental results can improve subsequent predictions.
This creates a pathway toward a more integrated drug discovery system in which computation and experimentation continuously inform each other.
For pharmaceutical companies, the strategic opportunity is not simply to adopt a larger AI model. It is to build the data, scientific, computational, and experimental infrastructure that allows foundation models to become part of a continuously learning discovery engine.
Drug Discovery is entering a new era as artificial intelligence foundation models change how researchers investigate diseases, identify potential drug targets, and design new therapeutic candidates. These models learn patterns from large datasets, including molecular structures, protein sequences, biological experiments, scientific literature, and chemical information.
Unlike traditional computational tools designed for a single task, foundation models can often be adapted to multiple research applications. They may help scientists predict molecular properties, explore chemical structures, analyze biological interactions, and generate ideas for new compounds.
As pharmaceutical companies face rising research costs and lengthy development timelines, these technologies offer an opportunity to make early-stage research more efficient. However, their value depends on reliable data, rigorous validation, and experimental evidence.
The Future of AI-Driven Drug Discovery
Future foundation models may combine molecular structures, biological measurements, clinical information, and experimental results within more integrated research systems.
Multimodal models could help researchers connect different forms of scientific evidence, while AI agents may assist with selected research tasks such as literature analysis, experiment planning, and data interpretation.
Another promising direction is the integration of computational predictions with automated laboratories. Experimental results can be used to refine models, helping research teams iteratively improve candidate selection.
Even with these developments, computational performance alone will not determine success. New medicines must demonstrate appropriate safety and efficacy through rigorous preclinical studies and clinical trials.
How Pharmaceutical Companies Are Adopting Foundation Models
Pharmaceutical companies and biotechnology startups are exploring foundation models through internal research platforms, partnerships with AI developers, and specialized computational biology programs.
Some organizations focus on protein modeling and target identification, while others develop systems for molecular generation, chemical property prediction, or analysis of biological datasets.
Successful adoption requires integration with existing research workflows. Teams need access to high-quality data, suitable computing resources, and experimental facilities capable of testing model-generated hypotheses.
Companies should also evaluate AI systems using measurable criteria, including prediction accuracy, experimental success rates, reproducibility, and the time required to move candidates through early research.
Challenges and Limitations
Despite rapid progress, foundation models face important technical and scientific challenges.
Data quality: Training datasets may contain missing information, inconsistent measurements, or biases that affect predictions.
Biological complexity: Disease mechanisms often involve multiple interacting pathways that are difficult to represent computationally.
Model reliability: A model may generate convincing predictions that fail when tested experimentally.
Reproducibility: Researchers need documented methods, suitable benchmarks, and independent validation to compare results reliably.
Intellectual property: Organizations must consider ownership, licensing, data provenance, and the legal implications of AI-generated discoveries.
Regulatory expectations: AI-assisted research must ultimately support appropriate evidence for the quality, safety, and efficacy of a therapeutic product.
Addressing these challenges requires collaboration between computational scientists, medicinal chemists, biologists, clinicians, and regulatory specialists.
Benefits of Foundation Models for Pharmaceutical Research
Foundation models offer several potential advantages across early-stage research.
-
Faster analysis: AI can process large datasets and identify patterns more quickly than many manual workflows.
-
Broader exploration: Generative models can suggest chemical structures that researchers may not have considered.
-
Improved prioritization: Predictive systems can help rank candidates for further investigation.
-
Research integration: Models can combine insights from chemical, biological, and scientific information sources.
-
More efficient experimentation: Better prioritization may reduce time spent testing less promising candidates.
-
New research opportunities: AI-generated hypotheses can help scientists explore biological mechanisms and therapeutic strategies.
These advantages are potential benefits rather than guaranteed outcomes. The actual impact varies across research programs and depends on experimental confirmation.
1. Identifying New Drug Targets
Finding the right biological target is an important early step in pharmaceutical research. Foundation models can analyze genomic, proteomic, and other biological datasets to identify patterns associated with diseases.
These systems may help researchers generate hypotheses about proteins, genes, or biological pathways involved in disease progression. Scientists can then investigate whether modifying a particular target could produce a meaningful therapeutic effect.
Target identification still requires biological validation because statistical associations do not necessarily demonstrate a causal relationship.
2. Designing New Molecules
Generative AI models can propose molecular structures with selected characteristics. Researchers may specify desired properties, such as binding potential, solubility, stability, or compatibility with a particular biological target.
This approach can expand the range of compounds considered during early research. Instead of evaluating only molecules already available in chemical libraries, teams can explore new candidates generated computationally.
Nevertheless, generated compounds must undergo chemical synthesis, laboratory testing, and further evaluation before their therapeutic potential can be established.
3. Predicting Protein Structure and Interactions
Protein structure and molecular interactions are central to understanding biological processes. AI systems can support predictions about protein structures and possible interactions between proteins and small molecules.
These predictions can help researchers formulate hypotheses about how a potential medicine might interact with its target.
However, predicted structures and binding scores are not substitutes for experimental measurements. Biological systems are complex, and real-world behavior can differ from computational predictions.
4. Improving Virtual Screening
Traditional screening may involve testing large numbers of compounds to identify candidates worth investigating further. AI-assisted virtual screening can prioritize compounds according to predicted properties and potential biological activity.
Foundation models may help researchers combine information from different datasets and identify candidates for laboratory evaluation.
This can improve the allocation of research resources, although the quality of the results depends on the training data, model design, and validation process.
5. Supporting Drug Repurposing
Drug repurposing involves investigating whether an existing medicine may be useful for a different disease or patient population.
Foundation models can analyze biomedical literature, molecular information, disease pathways, and experimental findings to suggest potential new uses for known compounds.
These suggestions may provide valuable starting points for research. However, a proposed new use requires appropriate preclinical and clinical evidence before it can be adopted in medical practice.
